Vmbook Online ordering

Threshold Pharmaceuticals Inc

Threshold Pharmaceuticals, Inc. was a biotechnology company located in South San Francisco, California, that focused on the discovery and development of drugs targeting cancer, cancer stem cells, and angiogenesis.

On February 15, 2017, Merrimack Pharmaceuticals acquired Threshold Pharmaceuticals and became a wholly-owned subsidiary. Its ticker symbol was THLD. Its most advanced product candidate was evofosfamide (previously known as TH-302), a hypoxia-activated prodrug that was in Phase 3 clinical trials for the treatment of soft tissue sarcoma. The company expected evofosfamide to be its first commercial product. In addition, the company was developing TH-400, a preclinical stage drug candidate. The company had an agreement with Merck KGaA (not Merck & Co.) for the development and commercialization of TH-302 in certain territories outside of North America.

On September 12, 2012, Threshold Pharmaceuticals priced its initial public offering of 5,750,000 shares of its common stock at $14 a share. The stock began trading on the NASDAQ exchange under the ticker symbol "THLD." The company raised $80 million in the offering, and shares rose 18% on the first day of trading.

Several analysts rated the stock as a buy, including Citigroup, UBS, Jefferies, and Leerink Swann.

On February 15, 2017, Merrimack Pharmaceuticals acquired Threshold Pharmaceuticals. The acquisition added Threshold's lead product, evofosfamide, to Merrimack's pipeline.